Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone

NCT00567710 is registered in ClinicalTrials.gov with BioLineRx, Ltd. as lead sponsor.

NCT NCT00567710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00567710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone
Lead sponsor
BioLineRx, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
September 30, 2009
Enrollment
360 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia